Biodexa Pharmaceuticals Files Routine 6-K
Ticker: BDRX · Form: 6-K · Filed: Jun 24, 2024 · CIK: 1643918
| Field | Detail |
|---|---|
| Company | Biodexa Pharmaceuticals PLC (BDRX) |
| Form Type | 6-K |
| Filed Date | Jun 24, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, routine-disclosure, foreign-private-issuer
Related Tickers: BDRX
TL;DR
Biodexa (BDRX) filed a 6-K, standard disclosure, no new info.
AI Summary
Biodexa Pharmaceuticals Plc, formerly Midatech Pharma Plc, filed a Form 6-K on June 24, 2024. This report is for the month of June 2024 and indicates the company files annual reports under Form 20-F. The filing does not contain specific financial figures or operational updates but serves as a routine disclosure for a foreign private issuer.
Why It Matters
This filing is a standard disclosure for foreign private issuers, indicating ongoing compliance with SEC reporting requirements without providing new material information.
Risk Assessment
Risk Level: low — The filing is a routine disclosure and does not contain any new material financial or operational information that would immediately impact risk.
Key Players & Entities
- Biodexa Pharmaceuticals Plc (company) — Registrant
- Midatech Pharma Plc (company) — Former company name
- June 24, 2024 (date) — Filing date
- Form 6-K (document) — Filing type
- Form 20-F (document) — Annual report form
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information which the issuer makes or is required to make public in its home country.
What is the filing date of this Form 6-K?
The filing date is June 24, 2024.
What was Biodexa Pharmaceuticals Plc formerly known as?
Biodexa Pharmaceuticals Plc was formerly known as Midatech Pharma Plc.
Does this filing contain specific financial results?
No, this Form 6-K filing does not appear to contain specific financial results or operational updates; it is a routine disclosure.
Which form does Biodexa Pharmaceuticals Plc use for its annual reports?
Biodexa Pharmaceuticals Plc files its annual reports under cover of Form 20-F.
Filing Stats: 264 words · 1 min read · ~1 pages · Grade level 15.1 · Accepted 2024-06-24 08:46:32
Filing Documents
- f6k_062424.htm (6-K) — 6KB
- exh_991.htm (EX-99.1) — 14KB
- 0001171843-24-003583.txt ( ) — 21KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Biodexa Pharmaceuticals PLC (Registrant) Date: June 24, 2024 /s/ Stephen Stamp Stephen Stamp Chief Executive Officer, Chief Financial Officer